WebJun 24, 2016 · β-D-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) is a cytidine analogue with potent and selective anti-hepatitis C virus (HCV) activity in the subgenomic HCV replicon assay, 90% effective concentration (EC 90)=4.6 +2.0 µM.The spectrum of activity and cytotoxicity profile of PSI-6130 was evaluated against a diverse panel of viruses and … Raymond F. Schinazi is an American organic medicinal chemist with expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), herpes, dengue fever, zika, … See more Schinazi was born on March 21, 1950, in Alexandria, Egypt to Jewish parents. In 1962, his family was sequestered by the Nasser regime and in 1964 they immigrated to Naples, Italy as refugees. Schinazi went to … See more Among the first drugs discovered and developed for treatment of HIV came through the collaboration between Dr. Dennis Liotta (Emory) … See more In 2004, Schinazi was one of the founders of Pharmasset, a company that would later go on to develop sofosbuvir. The name Pharmasset was derived from 'pharmaceutical … See more In 2024, Schinazi received the Chevalier de la Légion d’honneur, the French Legion of Honor, with the rank of knight. Established in 1802 by Napoleon … See more Schinazi is currently the Frances Winship Walters Professor of Pediatrics, Director of the Laboratory of Biochemical Pharmacology, and co-Director of the HIV Cure Scientific Working Group within the NIH-sponsored Emory University Center for AIDS Research … See more Schinazi's work led to the discovery of a second nucleoside analog, emtricitabine (FTC), subsequently resulting in a potent, safe nucleoside analog commonly used in treatment regimens. The discovery of FTC was first published in 1992 in Antimicrobial … See more Schinazi has also had a hand in the development of the other FDA-approved drugs Stavudine, Lamivudine, and Telbivudine. See more

The best backbone for HIV prevention, treatment, and elimination ...

WebRaymond F Schinazi Viral resistance is a worldwide problem mitigating the effectiveness of antiviral drugs. Mutations in the drug-targeting proteins are the primary mechanism for … WebMay 6, 2024 · Raymond F Schinazi's largest purchase order was 3,464,855 units, worth over $3.19M on April 23, 2015. Raymond F Schinazi's largest sale order was 575,000 units , worth over $1.7M on May 6, 2024. ravit zemach law office

Raymond F Schinazi PhD - OpenEmory Profile - Emory University

WebSchinazi is the founder of several biotechnology companies focusing on antiviral drug discovery and development, including Pharmasset Inc (acquired by Gilead), Triangle … WebRaymond F Schinazi, Frances Winship Walters Professor of Pediatrics, Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia 30033, USA., ... Weilert F, et al. Phase 1b efficacy and safety of NVR 3-778, a first-in-class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection. Hepatology. 2015; 62:1385A. WebFeb 1, 1998 · Schinazi RF. Author information. Affiliations. 1 author. 1. Veterans Affairs Medical Center, and Laboratory of Biochemical Pharmacology, Department of Pediatrics, … simple business property lease agreement